HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Chapelsky, M. C. Articles by Freed, M. I. Search for Related Content PubMed PubMed Citation Articles by Chapelsky, M. C. Articles by Freed, M. I.

Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency

From Clinical Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania (Dr. Chapelsky, Dr. Miller); the Clinical Pharmacology Unit, GlaxoSmithKline, Philadelphia, Pennsylvania (Dr. Thompson-Culkin); the Center for Clinical Research of the Austin Diagnostic Clinic, Austin, Texas (Dr. Sack); and the Clinical Pharmacokinetics Laboratory, Buffalo, New York (Dr. Blum) and GlaxoSmithKline, Collegeville, Pennsylvania (Dr. Freed).

This study investigated the effect of varying degrees of renal insufficiency on the pharmacokinetics of rosiglitazone. Subjects were stratified by estimated creatinine clearance: normal (> 80 mL/min; n = 12), mild renal insufficiency (60-80 mL/min; n = 15), moderate renal insufficiency (30-59 mL/min; n = 18), and severe renal insufficiency not requiring dialysis ( 29 mL/min; n = 12). Plasma rosiglitazone concentrations and protein binding were determined after a single oral 8-mg dose of rosiglitazone. Total and unbound pharmacokinetic parameters were generated using noncompartmental methods. AUC, C_max, and t_1/2 data were analyzed separately by ANOVA to provide point estimates and corresponding 95% confidence intervals. The pharmacokinetics of rosiglitazone was not markedly affected by mild, moderate, or severe renal insufficiency. Slight increases (approximately 10%-20%) in mean unbound AUC_0- values were observed for each insufficiency group compared to the normal group but were not considered to be clinically relevant. Patients with severe insufficiency exhibited a 38% increase in mean fraction unbound, leading to an increase in total clearance, which resulted in a 19% to 24% lower mean total AUC_0- and C_max values relative to the normal group. The rates of mild or moderate adverse events were similar for all groups; there were no severe adverse events. Impaired renal function does not markedly alter the pharmacokinetics of total or unbound rosiglitazone following a single dose of rosiglitazone. Therefore, the starting dose of rosiglitazone does not need to be adjusted in patients with renal impairment. Subsequent dose adjustments should be based on individual patient response.

This article has been cited by other articles:

				K. L. Cavanaugh Diabetes Management Issues for Patients With Chronic Kidney Disease Clin. Diabetes, July 1, 2007; 25(3): 90 - 97. [Abstract] [Full Text] [PDF]

				P. Iglesias and J. J Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621. [Abstract] [Full Text] [PDF]

				J.-F. Yale Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S7 - S10. [Abstract] [Full Text] [PDF]